Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204406 | 1.00 | MAPT (0.40) | MAPTKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL2206545 | 0.93 | KMT2A (0.42) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL2206548 | 0.93 | KMT2A (0.42) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL2201995 | 0.89 | POLB (0.41) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL2201993 | 0.89 | POLB (0.41) | KMT2AMEN1POLBALDH1A1HTT | |
| SCHEMBL2206894 | 0.86 | MMP8 (0.41) | MAPTLMNA | |
| SCHEMBL2206899 | 0.86 | MMP8 (0.41) | MAPTLMNA | |
| SCHEMBL2208968 | 0.84 | POLB (0.39) | KMT2APOLBATM | |
| SCHEMBL2207701 | 0.83 | MEN1 (0.40) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL2207704 | 0.83 | MEN1 (0.40) | KMT2AMEN1POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981886-B2 | Antibiotics derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-07-19 | — | — | US | claimed |
| EP-1888574-B1 | NEW ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | claimed |
| US-7981886-B2 | Antibiotics derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-07-19 | — | — | US | disclosed |
| EP-1888574-B1 | NEW ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080280888-A1 | Antibiotics Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280888-A1 | Antibiotics Derivatives | NR4A1, NR2C2, NR4A3 | MAPT 4688/4885KMT2A 1756/4885MEN1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.